Investments
165Portfolio Exits
15Funds
2Partners & Customers
3About bioVENTURE
Suzhou Industrial Park Bioventure Investment Management (苏州元生创投), dba bioVENTURE (元生创投), is an early-stage venture capital firm that focuses on life sciences.

Want to inform investors similar to bioVENTURE about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest bioVENTURE News
Feb 2, 2023
and now with the details Jeddah - Yasmine El Tohamy - RIYADH: The Saudi Central Bank has increased its interest rate by 25 basis points to 5.25 percent, echoing Wednesday’s move by the US Federal Reserve to curb inflation. A statement from the bank, also known as SAMA, noted its Reverse Repo rate has also increased to 4.75 percent. Inflation is on the rise in the Kingdom, with the annual rate rising to 3.3 percent in December, up from 2.9 percent in November. The Fed’s quarter-point interest rate hike follows months of larger increases, as it hiked 50 basis points in December, and 75 basis points in November, September, July and June. Despite recent signs of a slow down in the US economy, prices are running at their highest level since the early 1980s. While the US Central Bank’s decision was driven by its desire to lower high inflation, this played a part in driving the Gulf region’s monetary policy, as most of the region’s currencies are pegged to the dollar. Following the US Fed’s decision, regional central banks also swung into action to raise their interest rates – although Qatar chose to hold. The UAE's central bank increased its base rate to 4.65 percent, effective on Thursday, while the Central Bank of Oman hiked its Repo rate to reach 5.25 percent. Bahrain also raised its main rate by 25 basis points, with its one-week deposit facility rate rising to 5.5 percent, while the overnight deposit rate hit 5.25 percent. Qatar’s Central Bank said in a press release Wednesday that it would keep its rates unchanged, keeping its deposit rate at 5 percent, its lending rate at 5.5 percent, and its repo rates at 5.25 percent. As it was predicted that the country would mirror the Fed in early 2023 by the credit ratings agency Fitch in a report last month, this decision came somewhat as a surprise. The Central Bank of Kuwait, which raised its interest rate by 50 basis points last month, often acts separately and does not necessarily follow the Fed’s hikes. In addition, the Central Bank of Egypt is forecast to raise its overnight interest rates by 150 basis points at its regular monetary policy committee meeting on Thursday, a Reuters poll showed last Monday. The CBE increased its interest rates by an unprecedented 800 basis points over the last year alone, and has been involved in a constant series of currency devaluations. A poll of 13 analysts anticipated the bank to increase its deposit rate to 17.75 percent and its lending rate to 18.75 percent. These were the details of the news Saudi-based AJA Pharma and the UAE’s Bioventure agree deal to license and supply new pharmaceuticals for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new. It is also worth noting that the original news has been published and is available at Arab News and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
bioVENTURE Investments
165 Investments
bioVENTURE has made 165 investments. Their latest investment was in Eyedeal as part of their Series B on April 4, 2023.

bioVENTURE Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/23/2023 | Series B | Eyedeal | Yes | 4 | ||
2/16/2023 | Series A | Yingnuo Medical Technology | Yes | 4 | ||
1/30/2023 | Series A - II | Yuzhibo | Yes | 1 | ||
1/17/2023 | Series B | |||||
1/4/2023 | Series A |
Date | 4/23/2023 | 2/16/2023 | 1/30/2023 | 1/17/2023 | 1/4/2023 |
---|---|---|---|---|---|
Round | Series B | Series A | Series A - II | Series B | Series A |
Company | Eyedeal | Yingnuo Medical Technology | Yuzhibo | ||
Amount | |||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 4 | 4 | 1 |
bioVENTURE Portfolio Exits
15 Portfolio Exits
bioVENTURE has 15 portfolio exits. Their latest portfolio exit was Cryofocus Medtech on December 30, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/30/2022 | IPO | Public | 1 | ||
12/30/2022 | IPO | Public | 4 | ||
11/28/2022 | IPO | Public | 1 | ||
Date | 12/30/2022 | 12/30/2022 | 11/28/2022 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 1 | 4 | 1 |
bioVENTURE Fund History
2 Fund Histories
bioVENTURE has 2 funds, including YuanBio Venture Capital LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
3/30/2018 | YuanBio Venture Capital LP | Early-Stage Venture Capital | Open | 1 | |
Suzhou Industrial Park Xinjianyuan Biological Venture Capital Fund II LP |
Closing Date | 3/30/2018 | |
---|---|---|
Fund | YuanBio Venture Capital LP | Suzhou Industrial Park Xinjianyuan Biological Venture Capital Fund II LP |
Fund Type | Early-Stage Venture Capital | |
Status | Open | |
Amount | ||
Sources | 1 |
bioVENTURE Partners & Customers
3 Partners and customers
bioVENTURE has 3 strategic partners and customers. bioVENTURE recently partnered with Alvotech on November 11, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/29/2022 | Licensor | Iceland | According to the agreement , Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file , launch and commercialize Alvotech 's portfolio of licensed biosimilars once approved , under Bioventure 's exclusive strategic partnership with Alvotech in the region . | 6 | |
10/1/2022 | Licensor | ||||
3/3/2022 | Licensee |
Date | 11/29/2022 | 10/1/2022 | 3/3/2022 |
---|---|---|---|
Type | Licensor | Licensor | Licensee |
Business Partner | |||
Country | Iceland | ||
News Snippet | According to the agreement , Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file , launch and commercialize Alvotech 's portfolio of licensed biosimilars once approved , under Bioventure 's exclusive strategic partnership with Alvotech in the region . | ||
Sources | 6 |
bioVENTURE Team
1 Team Member
bioVENTURE has 1 team member, including current Managing Partner, Jie Chen.
Name | Work History | Title | Status |
---|---|---|---|
Jie Chen | Managing Partner | Current |
Name | Jie Chen |
---|---|
Work History | |
Title | Managing Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.